Organon & Co. (LON:0A9W)
7.67
-0.29 (-3.66%)
At close: Feb 11, 2026
Organon & Co. Revenue
In the year 2025, Organon & Co. had annual revenue of $6.22B USD, down -2.92%. Organon & Co. had revenue of $1.51B in the quarter ending December 31, 2025, a decrease of -5.34%.
Revenue
$6.22B
Revenue Growth
-2.92%
P/S Ratio
0.31
Revenue / Employee
$621.60K
Employees
10,000
Market Cap
1.47B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -187.00M | -2.92% |
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Currys | 9.02B |
| Wizz Air Holdings | 4.94B |
| SSP Group | 3.64B |
| Savills | 2.47B |
| Lancashire Holdings | 1.11B |
| Energean | 913.78M |
| Paragon Banking Group | 505.70M |
| Oxford Instruments | 481.80M |
Organon & Co. News
- 14 days ago - What Does the Market Think About Organon & Co? - Benzinga
- 14 days ago - Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 - Business Wire
- 15 days ago - Organon (OGN) Completes Sale of JADA System to Laborie Medical - GuruFocus
- 15 days ago - Organon Completes Divestiture of JADA® System to Laborie - Business Wire
- 22 days ago - Stone House Investment Management, LLC Buys 1,274 Shares of Organon & Co (OGN) - GuruFocus
- 22 days ago - Independence Bank of Kentucky Sells 500 Shares of Organon & Co (OGN) - GuruFocus
- 23 days ago - Organon Secures FDA Approval Extending NEXPLANON Use to Five Years - Nasdaq
- 23 days ago - Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Benzinga